Garde Capital, Inc. Abb Vie Inc. Transaction History

Garde Capital, Inc.

$1.44 Billion
Q2 2024

A detailed history of Garde Capital, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Garde Capital, Inc. holds 1,135 shares of ABBV stock, worth $200,838. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,135

Previous 1,194 4.94%

Holding current value

$200,838

Previous $217,000 10.14%

% of portfolio

0.01%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 19, 2024	SELL	$154.79 - $180.76 $9,132 - $10,664	-59 Reduced 4.94%	1,135 $195,000
Q1 2024 May 29, 2024	SELL	$159.82 - $182.1 $85,184 - $97,059	-533 Reduced 30.86%	1,194 $217,000
Q4 2023 Feb 21, 2024	SELL	$137.6 - $154.97 $368,080 - $414,544	-2,675 Reduced 60.77%	1,727 $268,000
Q3 2023 Nov 17, 2023	SELL	$133.59 - $154.65 $23,511 - $27,218	-176 Reduced 3.84%	4,402 $656,000
Q2 2023 Aug 28, 2023	BUY	$132.51 - $164.9 $606,630 - $754,912	4,578 New	4,578 $617,000
Q3 2019 Nov 13, 2019	SELL	$62.98 - $75.72 $237,119 - $285,085	-3,765 Closed	0 $0
Q2 2019 Aug 20, 2019	BUY	$65.7 - $83.98 $16,753 - $21,414	255 Added 7.26%	3,765 $274,000
Q1 2019 May 08, 2019	SELL	$77.14 - $90.79 $722,647 - $850,520	-9,368 Reduced 72.74%	3,510 $283,000
Q2 2018 Aug 20, 2018	SELL	$89.78 - $106.23 $74,607 - $88,277	-831 Reduced 6.06%	12,878 $1.19 Million
Q1 2018 May 16, 2018	SELL	$92.01 - $123.21 $1,748 - $2,340	-19 Reduced 0.14%	13,709 $1.3 Million
Q4 2017 Feb 23, 2018	SELL	$89.56 - $98.21 $11,732 - $12,865	-131 Reduced 0.95%	13,728 $1.33 Million
Q3 2017 Nov 17, 2017	BUY	$69.85 - $89.22 $968,051 - $1.24 Million	13,859	13,859 $1.23 Million

Others Institutions Holding ABBV

# of Institutions

3,848

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $313B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Garde Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Garde Capital, Inc. with notifications on news.

Account

Garde Capital, Inc. Abb Vie Inc. Transaction History